Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) Shares Pass Above Two Hundred Day Moving Average – Here’s What Happened

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM)’s share price passed above its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $47.38 and traded as high as $59.26. Global X Genomics & Biotechnology ETF shares last traded at $58.45, with a volume of 22,895 shares changing hands.

Global X Genomics & Biotechnology ETF Stock Performance

The business’s fifty day moving average is $49.60 and its 200-day moving average is $47.38. The firm has a market cap of $85.92 million, a P/E ratio of -24.98 and a beta of 1.16.

Global X Genomics & Biotechnology ETF Announces Dividend

The firm also recently declared a dividend, which was paid on Tuesday, July 7th. Stockholders of record on Monday, June 29th were paid a dividend of $0.0579 per share. The ex-dividend date of this dividend was Monday, June 29th. Global X Genomics & Biotechnology ETF’s dividend payout ratio (DPR) is presently -27.35%.

Institutional Trading of Global X Genomics & Biotechnology ETF

Several institutional investors have recently modified their holdings of the business. Jane Street Group LLC grew its position in shares of Global X Genomics & Biotechnology ETF by 7.7% in the 1st quarter. Jane Street Group LLC now owns 143,713 shares of the company’s stock valued at $1,143,000 after buying an additional 10,308 shares during the last quarter. Bank of America Corp DE raised its position in shares of Global X Genomics & Biotechnology ETF by 67.8% during the first quarter. Bank of America Corp DE now owns 119,795 shares of the company’s stock worth $5,240,000 after acquiring an additional 48,394 shares during the last quarter. Sei Investments Co. lifted its stake in shares of Global X Genomics & Biotechnology ETF by 110.4% in the second quarter. Sei Investments Co. now owns 23,073 shares of the company’s stock worth $194,000 after acquiring an additional 12,105 shares during the period. Smartleaf Asset Management LLC lifted its stake in shares of Global X Genomics & Biotechnology ETF by 30.9% in the second quarter. Smartleaf Asset Management LLC now owns 19,548 shares of the company’s stock worth $164,000 after acquiring an additional 4,615 shares during the period. Finally, U.S. Capital Wealth Advisors LLC bought a new stake in Global X Genomics & Biotechnology ETF in the fourth quarter valued at approximately $575,000. Institutional investors own 56.95% of the company’s stock.

About Global X Genomics & Biotechnology ETF

Complete Genomics, Inc is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center.